Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Dravet syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms GWPCARE2
  • Sponsors GW Pharmaceuticals; GW Research; Jazz Pharmaceuticals Inc

    • Most Recent Events

    • 23 Nov 2023 According to a Jazz Pharmaceuticals Inc media release, Epidiolex (cannabidiol oral solution), has been approved by Health Canada for use as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients 2 years of age and older, based on data from five double-blind, randomized, placebo-controlled Phase 3 clinical trials, with a total of 939 enrolled.
    • 01 Sep 2021 Results from NCT02224560, NCT02224690 NCT02091375, NCT02224703; evaluating safety of Cannabidiol in patients on Ketogenic Diet Therapy, presented at the 34th International Epilepsy Congress
    • 01 Sep 2021 Results of a pooled analysis (GWPCARE 1, 2, 3, and 4 studies) assessing the incidence and resolution of diarrhoea in patients taking CBD at 10 mg/kg/day (CBD10) or 20 mg/kg/day (CBD20), or matched placebo solution presented at the 34th International Epilepsy Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top